The U.S. Food and Drug Administration has approved Apellis Pharmaceuticals' Empaveli (pegcetacoplan) as the first treatment ...

Pegcetacoplan inhibits C3 activation by binding to C3 and its activation fragment C3b, thereby reducing C3 glomerular fragment deposition in patients with C3G and primary IC-MPGN.

The Philippines is breaking new ground in kidney transplant surgery with the adoption of the da Vinci Xi Robotic Surgical ...